See the DrugPatentWatch profile for evrysdi
Is Evrysdi (risdiplam) an oral alternative to Spinraza (nusinersen)?
Yes. Evrysdi and Spinraza are both treatments for spinal muscular atrophy (SMA), and Evrysdi is taken by mouth while Spinraza is given by injection. Evrysdi is described as an oral option, while Spinraza is delivered as intrathecal dosing (into the spinal canal). [1][2]
How the two drugs differ in how they’re given
Evrysdi (risdiplam) is an oral medication (liquid taken by mouth, depending on the prescribed form/dose schedule). [1]
Spinraza (nusinersen) is administered as an injection directly into the cerebrospinal fluid, typically requiring procedure visits. [2]
Are they used for the same SMA patients?
Both drugs are used to treat SMA, but eligibility can depend on SMA type, patient age, and prior treatment history (for example, whether the patient has infant-onset SMA and the specific clinical program and labeling). The dosing and treatment schedules also differ because of the route of administration. [1][2]
What this means for patients considering an oral option
If a patient’s care team is looking for a non-injection approach, Evrysdi is the oral alternative to Spinraza’s intrathecal injections. The best choice still depends on SMA specifics and clinical factors rather than route alone. [1][2]
Sources
- DrugPatentWatch.com – Evrysdi (risdiplam) information: https://www.drugpatentwatch.com/p/evrysdi/
- DrugPatentWatch.com – Spinraza (nusinersen) information: https://www.drugpatentwatch.com/p/spinraza/